In silico drug delivery modeling of a novel Everolimus Coated Balloon

Résumé fourni par la source

This study examines the drug elution process of a novel Everolimus Coated Balloon (ECB) that features a novel polymer mixture consisting of cellulose derivatives and accelerators, and Everolimus as the pharmaceutical component, based on commercially available PTCA balloon-catheter system. In this analysis, we utilized in silico postdeployment results comprising three distinct datasets of healthy porcine arteries undergoing PTCA with (a) Sirolimus, (b) Low-dose Everolimus, and (c) High-dose Everolimus. We developed a computational model that consists of the drug release from the balloon surface and the drug transport through the porous arterial wall given advection and diffusion properties. The comparative results of the current study highlight that: (a) among the high and low-dose Everolimus Eluting Balloons, diffusivity is the governing property and as such, respective amount of drug is eluted and bound by the arterial wall - effectively rendering the high-dose balloon powerful in its delivery properties, and (b) based on the diffusivity of Everolimus and Sirolimus, the Everolimus Eluting Balloons exhibit superior performance with respect to total bound drug of the arterial wall.Clinical Relevance-The approach described in this article is a step farther toward precision drug release from DCB prediction. Furthermore, our study's findings demonstrate that higher drug concentration in the coating leads to higher binding amounts; this information could be utilized to inform the creation of novel Drug Coated Balloon (DCB).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.